Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBAI20 hepatitis B vaccine in hepatitis B vaccine non-responders
2016-002720-91Phase 2Completed
- Sponsor
- CyTuVax
- Start
- Nov 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of HBAI20 and Recombivax HB in hepatitis B (HBV) (2 arms), sponsored by CyTuVax. Primary endpoints: Seroprotection rate, Hepatitis B antibody titer and 2 more. Started Nov 2016; status: completed.
02
Drugs
HBAI20Recombivax HB
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2016-002720-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002720-91.